Name: MILLIPLEX<SUP>®</SUP> Human CD8+ T Cell Panel
Brand: MM

产品名称

MILLIPLEX^® Human CD8+ T Cell Panel, Premixed Human CD8+ T Cell 17-Plex Panel

species reactivity

human

manufacturer/tradename

Milliplex^®

Quality Level

200

packaging

1 ea of

assay range

standard curve range: 0.4-1,500 pg/mL
(IL-6)
standard curve range: 0.5-2,000 pg/mL
(TNFα)
standard curve range: 1-3,500 pg/mL
(MIP-1α)
standard curve range: 1-5,000 pg/mL
(Granzyme B)
standard curve range: 1-5,000 pg/mL
(IFNγ)
standard curve range: 1-5,000 pg/mL
(IL-5)
standard curve range: 10-50,000 pg/mL
(Perforin)
standard curve range: 10-50,000 pg/mL
(sFasL)
standard curve range: 2-10,000 pg/mL
(IL-4)
standard curve range: 2-10,000 pg/mL
(sCD137)
standard curve range: 2-7,500 pg/mL
(IL-13)
standard curve range: 2-7,500 pg/mL
(IL-2)
standard curve range: 20-100,000 pg/mL
(Granzyme A)
standard curve range: 4-15,000 pg/mL
(GM-CSF)
standard curve range: 400-1,650,000 pg/mL
(sFas)
standard curve range: 5-20,000 pg/mL
(IL-10)
standard curve range: 7-30,000 pg/mL
(MIP-1β)

technique(s)

multiplexing: suitable

input

serum plasma (Cell culture, cell culture supernatants)

detection method

fluorometric (Luminex^® xMAP^® technology)

shipped in

wet ice

storage temp.

2-8°C

Biochem/physiol Actions

Cross-reactivity between the antibodies and any of the other analytes in this panel is non-detectable or negligible.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

For research use only. Not for use in diagnostic procedures.Label License/Sticker for Assay Product:By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.

For research use only. Not for use in diagnostic procedures.Label License/Sticker for Assay Product:By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.

General description

CD8+ T cells (also known as cytotoxic T cells, cytolytic T cells and killer T cells) belong to a sub-group of T cells capable of inducing the death of infected somatic or tumor cells. T cells that bind weakly to Major Histocompatibility Complex (MHC) self-antigens are positively selected into single-positive CD4+ or CD8+ T cells in the thymus. Those CD8+ T cells that survive and mature after activation become cytotoxic cells, expressing T-cell receptors (TCRs) capable of recognizing specific antigenic peptides bound to Class I MHC molecules and the glycoprotein CD8. Affinity between the CD8 protein and the MHC molecule helps to keep the cytotoxic T cell and target closely bound during antigen specific activation. Once activated, CD8+ T cells are generally classified as having a predefined cytotoxic role within the immune system and undergo IL-2 induced clonal expansion, which increases the number of cells specific for the target antigen. The CD8+ T cells then travel throughout the body in search of antigen-positive somatic/tumor cells.

The Luminex^® xMAP^® platform uses a magnetic bead immunoassay format for ideal speed and sensitivity to quantitate multiple analytes simultaneously, dramatically improving productivity while conserving valuable sample volume.

Panel Type: Cytokines/Chemokines

CD8+ T cells (also known as cytotoxic T cells, cytolytic T cells and killer T cells) belong to a sub-group of T cells capable of inducing the death of infected somatic or tumor cells. T cells that bind weakly to Major Histocompatibility Complex (MHC) self-antigens are positively selected into single-positive CD4+ or CD8+ T cells in the thymus. Those CD8+ T cells that survive and mature after activation become cytotoxic cells, expressing T-cell receptors (TCRs) capable of recognizing specific antigenic peptides bound to Class I MHC molecules and the glycoprotein CD8. Affinity between the CD8 protein and the MHC molecule helps to keep the cytotoxic T cell and target closely bound during antigen specific activation. Once activated, CD8+ T cells are generally classified as having a predefined cytotoxic role within the immune system and undergo IL-2 induced clonal expansion, which increases the number of cells specific for the target antigen. The CD8+ T cells then travel throughout the body in search of antigen-positive somatic/tumor cells.

Other Notes

Sensitivity: Refer to kit protocol for sensitivities of individual biomarkers.

Preparation Note

Recommended storage for kit components is 2 - 8°C.

Legal Information

Luminex is a registered trademark of Luminex Corp

MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany

xMAP is a registered trademark of Luminex Corp

Application

MILLIPLEX^® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze 17 analytes in human serum, plasma, and cell culture supernatants.Analytes included: GM-CSF, sCD137, IFNγ, sFas, sFasL, Granzyme A, Granzyme B, IL-2, IL-4, IL-5, IL-6, IL-10, IL-13, MIP-1α, MIP-1β, TNF-α, PerforinAssay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.

Features and Benefits

Extensive Analyte Coverage: This panel comprises 15 crucial analytes associated with CD8+ T cell function, including GM-CSF, IFNγ, IL-2, Granzyme A, and Perforin, facilitating in-depth analysis of immune responses.
Increased Productivity: The multiplex format significantly improves throughput, allowing researchers to analyze more samples in less time, which is critical in high-throughput research environments.
Premixed Formulation: Premixed options reduce preparation time and minimize the risk of pipetting errors, ensuring consistency and reliability in assay results.
Diverse Sample Compatibility: Suitable for a variety of biological samples, including serum, plasma, tissue and cell lysates, as well as culture supernatants, making it adaptable for different research needs.

pictograms

GHS08,GHS05,GHS07,GHS09

signalword

Danger

hcodes

H302 + H312 + H332,H317,H318,H373,H411

pcodes

P273 - P280 - P302 + P352 + P312 - P304 + P340 + P312 - P305 + P351 + P338 - P314

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

target_organs

Respiratory Tract

存储类别

10 - Combustible liquids

wgk

WGK 3

法规信息

新产品

此项目有

分析证书(COA)

输入产品批号来搜索分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

B-cells with a FasL expressing regulatory phenotype are induced following successful anti-tuberculosis treatment.

Ilana C van Rensburg et al.

Immunity, inflammation and disease, 5(1), 57-67 (2017-03-03)

Studies show that B-cells, in addition to producing antibodies and antigen-presentation, are able to produce cytokines as well. These include regulatory cytokines such as IL-10 by regulatory B-cells. Furthermore, a rare regulatory subset of B-cells have the potential to express

CIGB-258, a peptide derived from human heat-shock protein 60, decreases hyperinflammation in COVID-19 patients.

M Hernandez-Cedeño et al.

Cell stress & chaperones, 26(3), 515-525 (2021-02-26)

Hyperinflammation distinguishes COVID-19 patients who develop a slight disease or none, from those progressing to severe and critical conditions. CIGB-258 is a therapeutic option for the latter group of patients. This drug is an altered peptide ligand (APL) derived from

Systemic translation of locally infiltrated epidermal growth factor in diabetic lower extremity wounds.

Ariana García-Ojalvo et al.

International wound journal, 16(6), 1294-1303 (2019-08-21)

Diabetic foot ulcer is one of the most frightened diabetic complications leading to amputation disability and early mortality. Diabetic wounds exhibit a complex networking of inflammatory cytokines, local proteases, and reactive oxygen and nitrogen species as a pathogenic polymicrobial biofilm

Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment.

Sujita Sukumaran et al.

Cancer discovery, 8(8), 972-987 (2018-06-09)

The adoptive transfer of chimeric antigen receptor (CAR)-modified T cells has produced tumor responses even in patients with refractory diseases. However, the paucity of antigens that are tumor selective has resulted, on occasion, in "on-target, off-tumor" toxicities. To address this

Vitreous Cytokine Expression and a Murine Model Suggest a Key Role of Microglia in the Inflammatory Response to Retinal Detachment.

Lee Kiang et al.

Investigative ophthalmology & visual science, 59(8), 3767-3778 (2018-07-27)

Retinal detachment (RD) separates the retina from the underlying retinal pigment epithelium, resulting in a gradual degeneration of photoreceptor (PR) cells. It is known that RD also results in an inflammatory response, but its contribution to PR degeneration is unknown.

查看所有相关文献

MILLIPLEX® Human CD8+ T Cell Panel

Premixed Human CD8+ T Cell 17-Plex Panel

选择尺寸

关于此项目

主要文件

属性